XT
INTS icon

XTX Topco’s Intensity Therapeutics INTS Stock Holding History

XTX Topco’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-982
Closed -$7.54K – 2882
2025
Q2 		$7.54K Buy
+982
New +$20.2K ﹤0.01% 2245

Other funds holding INTS

SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
SFGP
Stonebridge Financial Group (Pennsylvania) Wormleysburg, Pennsylvania $1.32B AUM 23.07% 1-Year Est. Return

XTX Topco's INTS Position: Q3 2025 in Review

XTX Topco sold out of Intensity Therapeutics (INTS) in Q3 2025, closing a stake of 982 shares — an estimated $7.54K sold.

XTX Topco first reported a position in INTS in Q2 2025 and held it in 1 quarter. The position peaked at $7.54K in Q2 2025. 26 funds tracked by Wall St. Rank hold INTS as of Q3 2025.

  • XTX Topco reported no remaining Intensity Therapeutics position as of Q3 2025 after selling out during the quarter.
  • XTX Topco sold 982 Intensity Therapeutics shares in Q3 2025, an estimated $7.54K.
  • XTX Topco first reported a position in Intensity Therapeutics in Q2 2025 and held it in 1 quarter.
  • XTX Topco's Intensity Therapeutics position peaked at $7.54K in Q2 2025.
  • 26 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q3 2025.

Based on XTX Topco's 13F filing for Q3 2025, filed 14 Nov 2025.